Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 7528 · GAP Supply Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 353b Outsourcing facilities

+2 −2Shown
More for 21 U.S.C. § 353b
Read § 353bOnly this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    in subsection (a)(2)(A)(ii), by striking at the time and inserting within 180 calendar days; and

  2. Carried out:

    in subsection (d)(2)(A), by striking at the time and inserting within 180 calendar days.

§ 353b(a)(2)Bulk drug substances(A)–(C)

Start of § 353b to (a)(2)(A)(i)(II) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(A)(i)(III)(III) (III)
publishing a notice in the Federal Register designating bulk drug substances for inclusion on the list; orpublishing a notice in the Federal Register designating bulk drug substances for inclusion on the list; or
(A)(ii)(ii) (ii)
the drug compounded from such bulk drug substance appears on the drug shortage list in effect under section 356e of this title [struck: at] [struck: the] [struck: time] of compounding, distribution, and dispensing;the drug compounded from such bulk drug substance appears on the drug shortage list in effect under section 356e of this title [inserted: within] [inserted: 180] [inserted: calendar] [inserted: days ]of compounding, distribution, and dispensing;
(B)(B) (B)
if an applicable monograph exists under the United States Pharmacopeia, the National Formulary, or another compendium or pharmacopeia recognized by the Secretary for purposes of this paragraph, the bulk drug substances each comply with the monograph;if an applicable monograph exists under the United States Pharmacopeia, the National Formulary, or another compendium or pharmacopeia recognized by the Secretary for purposes of this paragraph, the bulk drug substances each comply with the monograph;
(C)(C) (C)
the bulk drug substances are each manufactured by an establishment that is registered under section 360 of this title (including a foreign establishment that is registered under section 360(i) of this title); andthe bulk drug substances are each manufactured by an establishment that is registered under section 360 of this title (including a foreign establishment that is registered under section 360(i) of this title); and

§ 353b(d)Definitions(2)–(3)

(a)(2)(D)–(d)(1) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(2)(2) (2)
The term “essentially a copy of an approved drug” means—The term “essentially a copy of an approved drug” means—
(2)(A)(A) (A)
a drug that is identical or nearly identical to an approved drug, or a marketed drug not subject to section 353(b) of this title and not subject to approval in an application submitted under section 355 of this title, unless, in the case of an approved drug, the drug appears on the drug shortage list in effect under section 356e of this title [struck: at] [struck: the] [struck: time] of compounding, distribution, and dispensing; ora drug that is identical or nearly identical to an approved drug, or a marketed drug not subject to section 353(b) of this title and not subject to approval in an application submitted under section 355 of this title, unless, in the case of an approved drug, the drug appears on the drug shortage list in effect under section 356e of this title [inserted: within] [inserted: 180] [inserted: calendar] [inserted: days ]of compounding, distribution, and dispensing; or
(2)(B)(B) (B)
a drug, a component of which is a bulk drug substance that is a component of an approved drug or a marketed drug that is not subject to section 353(b) of this title and not subject to approval in an application submitted under section 355 of this title, unless there is a change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.a drug, a component of which is a bulk drug substance that is a component of an approved drug or a marketed drug that is not subject to section 353(b) of this title and not subject to approval in an application submitted under section 355 of this title, unless there is a change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.
(3)(3) (3)
The term “approved drug” means a drug that is approved under section 355 of this title and does not appear on the list described in subsection (a)(4) of drugs that have been withdrawn or removed from the market because such drugs or components of such drugs have been found to be unsafe or not effective.The term “approved drug” means a drug that is approved under section 355 of this title and does not appear on the list described in subsection (a)(4) of drugs that have been withdrawn or removed from the market because such drugs or components of such drugs have been found to be unsafe or not effective.

Rest of § 353b unchanged

Step through the changes